Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib vs adalimumab for JIA-associated uveitis in children and adolescents
2023-505811-18-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of baricitinib in juvenile idiopathic arthritis-associated uveitis (JIA-U) and uveitis (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: SUN criteria uveitis response in most affected eye through week 24. Planned start Nov 2019; status: authorised.
02
Drugs
baricitinib
03
Conditions
juvenile idiopathic arthritis-associated uveitis (JIA-U)uveitis
Beyond the preview
Go deeper on 2023-505811-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505811-18-00.